Jennison Associates
GYRE icon

Jennison Associates’s Gyre Therapeutics GYRE Stock Holding History

Jennison Associates’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-704
Closed -$1.4M – 736
2014
Q3 		$1.4M Sell
704
-62
-8% -$153K ﹤0.01% 615
2014
Q2 		$2.72M Sell
766
-122
-14% -$398K ﹤0.01% 545
2014
Q1 		$3.32M Buy
888
+3
+0.3% +$11.1K ﹤0.01% 549
2013
Q4 		$2.89M Buy
885
+3
+0.3% +$11.8K ﹤0.01% 542
2013
Q3 		$3.69M Hold
882
– – ﹤0.01% 520
2013
Q2 		$2.97M Buy
+882
New +$3.36M ﹤0.01% 510

Other funds holding GYRE

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jennison Associates's GYRE Position: Q4 2014 in Review

Jennison Associates sold out of Gyre Therapeutics (GYRE) in Q4 2014, closing a stake of 704 shares — an estimated $1.4M sold.

Jennison Associates first reported a position in GYRE in Q2 2013 and held it in 6 quarters. The position peaked at $3.69M in Q3 2013. 56 funds tracked by Wall St. Rank hold GYRE as of Q4 2014.

  • Jennison Associates reported no remaining Gyre Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Jennison Associates sold 704 Gyre Therapeutics shares in Q4 2014, an estimated $1.4M.
  • Jennison Associates first reported a position in Gyre Therapeutics in Q2 2013 and held it in 6 quarters.
  • Jennison Associates's Gyre Therapeutics position peaked at $3.69M in Q3 2013.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2014.

Based on Jennison Associates's 13F filing for Q4 2014, filed 6 Feb 2015.